查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972957

生長因子市場：市場洞察、競爭格局及市場預測（2033 年）

Growth Factors Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 200 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球生長因子市場預計將從 2026 年的 24 億美元顯著增長至 2033 年的 39 億美元，複合年增長率 (CAGR) 高達 5.7%。這一增長主要得益於生物技術、藥物研發和再生醫學領域對生長因子的日益廣泛應用，以及全球慢性病和癌症發病率的上升。

市場概覽

生長因子是天然存在的蛋白質，能夠調節細胞生長、增生和分化。它們在傷口癒合、組織再生和標靶治療中發揮著至關重要的作用，使其成為現代生物醫學研究和臨床應用中不可或缺的工具。 它們在腫瘤學、血液學和再生醫學領域的廣泛應用，正推動其在研究和治療流程中廣泛應用。

重組DNA技術和蛋白質工程等技術的進步，使得高純度生長因子的生產成為可能，提高了其在研究和商業應用中的功效和可用性。 製藥和生技公司對蛋白質療法的投資不斷增加，進一步推動了市場的擴張。

市場驅動因素

推動該市場成長的因素如下：

  • 1. 慢性病和癌症發生率上升：隨著全球癌症、心血管疾病和糖尿病發生率的上升，標靶治療和再生醫學解決方案的重要性日益凸顯，對生長因子的需求也隨之增長。
  • 2. 細胞療法和再生醫學的進步：生長因子在幹細胞研究、組織工程和體外生產中促進細胞增殖和分化，推動了其在先進治療應用中的應用。
  • 3.政府支持與資助：全球監管機構和政府都在資助生物技術和再生醫學研究，促進生長因子在臨床和研究領域的應用。
  • 4. 製藥業研發投入的擴大：製藥和生技公司正在增加對蛋白質療法的投資，從而增強了研發項目對生長因子的需求。

商機

生長因子市場為製造商和投資者提供了許多充滿前景的機會：

  • 創新療法：生長因子對於再生醫學、癌症治療和傷口癒合產品的開發至關重要，這創造了巨大的研發和商業化機會。
  • 新興市場成長：亞太和拉丁美洲不斷擴大的醫療基礎設施和研究計畫為市場擴張提供了途徑。
  • 策略合作：與研究中心、合約研究組織 (CRO) 和學術機構建立合作關係，可加速產品開發並增強市場影響力。

區域分析

  • 北美：得益於強大的製藥和生物技術產業基礎、完善的研究基礎設施以及政府對先進療法的資助，該市場處於領先地位。
  • 歐洲：在再生醫學、蛋白質療法的高普及率以及支持性監管框架的推動下，呈現穩定成長態勢。
  • 亞太地區：預計成長速度最快，這主要得益於醫療保健支出的增加、生物技術生態系統的發展以及中國、日本和印度研究活動的拓展。
  • 拉丁美洲：醫療保健基礎設施的改善、與全球生物技術公司合作的加強以及研究能力的提升，都為該地區的增長提供了支持。
  • 非洲：儘管規模較小，但由於人們對先進療法的認識不斷提高以及生物技術解決方案的日益普及，該市場正在穩步擴張。

主要參與者

市場競爭非常激烈，主要參與者專注於研發、產品開發和商業化。

主要公司包括：
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Hoffmann-La Roche Ltd.
  • Applied Biological Materials (abm), Inc.
  • Abcam plc
  • GE Healthcare
  • Cell Signaling Technology, Inc.
  • Meridian Bioscience Inc.
  • Sartorius CellGenix GmbH
  • Bio-Techne Corporation
  • Proteintech Group, Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • Akron Biotech
  • Sino Biological Inc.
  • Repligen Corporation
  • LEADGENE BIOMEDICAL, INC.
  • PeproTech Inc.

這些公司正在拓展產品組合，加大研發投入，並建立策略合作夥伴關係，以開發具有更高穩定性、特異性和治療應用的下一代生長因子。

市場區隔

依產品類型：

  • 轉化生長因子 (TGF)
  • 激活素
  • 骨形態發生蛋白 (BMP)
  • TGF-β 蛋白
  • 表皮生長因子 (EGF)
  • 血小板衍生生長因子 (PDGF)
  • 纖維母細胞生長因子 (FGF)
  • 類胰島素生長因子 (IGF)
  • 血管內皮生長因子 (VEGF)
  • 肝細胞生長因子 (HGF)
  • 腫瘤壞死因子 (TNF)
  • 白血球介素
  • 其他

依應用:

  • 腫瘤學
  • 血液學
  • 傷口癒合
  • 皮膚病學
  • 心血管疾病與糖尿病
  • 細胞療法與體外生產
  • 其他

依最終使用者劃分：

  • 製藥公司和生技公司
  • 研究中心和學術機構
  • 合約研發組織

依地區劃分：

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

目錄

第一章 摘要整理

第二章：市場概述

  • 市場定義與細分
  • 市場動態
    • 驅動因素
    • 限制因素
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監理分析
  • 價格趨勢分析
    • 當前價格與未來預測（2025-2033年）
    • 價格影響因素

第三章 全球成長因素市場展望（2020-2033年）
  • 全球成長因素市場展望（依產品類型與價值劃分，單位：十億美元） 2020–2033
    • 轉化生長因子 (TGF)
    • 表皮生長因子 (EGF)
    • 血小板衍生生長因子 (PDGF)
    • 纖維母細胞生長因子 (FGF)
    • 類胰島素生長因子 (IGF)
    • 血管內皮生長因子 (VEGF)
    • 肝細胞生長因子 (HGF)
    • 腫瘤壞死因子 (TNF)
    • 白血球介素
    • 其他
  • 全球生長因子市場展望，依應用領域劃分，價值（十億美元），2020–2033 年（33 年）
    • 腫瘤學
    • 血液學
    • 傷口癒合
    • 皮膚病學
    • 心血管疾病與糖尿病
    • 細胞療法與體外製造業
    • 其他
  • 全球成長因子市場展望（依最終用戶劃分，價值（十億美元）），2020-2033 年
    • 製藥和生技公司
    • 研究中心和學術機構
    • 合約研究公司
  • 全球成長因子市場展望（依地區劃分，價值（十億美元）），2020-2033 年
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第四章：北美成長因子市場展望，2020-2033 年

第五章：歐洲成長因子市場展望，2020-2033 年

第六章：亞太地區成長因子市場展望， 2020–2033

第七章：拉丁美洲成長因子市場展望，2020–2033

第八章：中東與非洲成長因子市場展望，2020–2033

第9章 競爭情形

  • 企業對市場區隔熱圖
  • 企業市場佔有率分析，2025年
  • 競爭儀表板
  • 企業簡介
    • Lonza Group AG
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Hoffmann-La Roche Ltd.
    • Applied Biological Materials (abm), Inc.
    • Abcam plc
    • GE Healthcare
    • Cell Signaling Technology, Inc.
    • Meridian Bioscience Inc.
    • Sartorius CellGenix GmbH

第10章 附錄

簡介目錄

The global Growth Factors Market is anticipated to grow significantly, rising from $2.4 billion in 2026 to $3.9 billion by 2033, at a robust compound annual growth rate (CAGR) of 5.7%. This growth is primarily driven by the increasing adoption of growth factors in biotechnology, pharmaceutical research, and regenerative medicine, alongside the rising prevalence of chronic diseases and cancer worldwide.

Market Overview

Growth factors are naturally occurring proteins that regulate cellular growth, proliferation, and differentiation. They play a vital role in wound healing, tissue regeneration, and targeted therapeutics, making them essential tools in modern biomedical research and clinical applications. Their versatility in oncology, hematology, and regenerative medicine has driven widespread adoption across research and therapeutic pipelines.

Technological advancements, including recombinant DNA technology and protein engineering, have enabled the production of high-purity growth factors, improving their efficacy and availability for research and commercial applications. Increasing investments by pharmaceutical and biotechnology companies in protein-based therapeutics are further driving market expansion.

Market Drivers

Several factors are fueling growth in this market:

  • 1. Rising Chronic Disease and Cancer Incidence: The global increase in cancer, cardiovascular disorders, and diabetes is boosting demand for growth factors as targeted therapies and regenerative solutions gain importance.
  • 2. Advancements in Cell Therapy and Regenerative Medicine: Stem cell research, tissue engineering, and ex-vivo manufacturing require growth factors to enhance cell proliferation and differentiation, driving their adoption in advanced therapeutic applications.
  • 3. Government Support and Funding: Regulatory agencies and governments worldwide are funding biotechnology and regenerative medicine research, promoting the use of growth factors in clinical and research settings.
  • 4. Expansion of Pharmaceutical R&D: Pharmaceutical and biotechnology firms are increasingly investing in protein-based therapeutics, strengthening demand for growth factors across research and drug development programs.

Business Opportunities

The growth factors market presents several lucrative opportunities for manufacturers and investors:

  • Innovative Therapeutics: Growth factors are critical to developing regenerative therapies, cancer treatments, and wound healing products, creating significant opportunities for research and commercialization.
  • Emerging Market Growth: Increasing healthcare infrastructure and research initiatives in Asia Pacific and Latin America provide avenues for market expansion.
  • Strategic Collaborations: Partnerships with research centers, contract research organizations (CROs), and academic institutions can accelerate product development and strengthen market presence.

Regional Analysis

  • North America: Dominates the market due to a strong pharmaceutical and biotechnology ecosystem, well-established research infrastructure, and substantial government funding for advanced therapeutics.
  • Europe: Experiences steady growth driven by high adoption of regenerative therapies, protein-based therapeutics, and supportive regulatory frameworks.
  • Asia Pacific: Projected to grow at the fastest rate, fueled by increasing healthcare expenditure, a growing biotechnology ecosystem, and expanding research initiatives in China, Japan, and India.
  • Latin America: Growth is supported by improving healthcare infrastructure, rising collaborations with global biotech firms, and expanding research capabilities.
  • Middle East & Africa: Though smaller in size, the market is expanding steadily due to increasing awareness of advanced therapies and growing adoption of biotechnology-based solutions.

Key Players

The market is highly competitive, with key players focusing on research, product development, and commercialization. Leading companies include:

  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Hoffmann-La Roche Ltd.
  • Applied Biological Materials (abm), Inc.
  • Abcam plc
  • GE Healthcare
  • Cell Signaling Technology, Inc.
  • Meridian Bioscience Inc.
  • Sartorius CellGenix GmbH
  • Bio-Techne Corporation
  • Proteintech Group, Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • Akron Biotech
  • Sino Biological Inc.
  • Repligen Corporation
  • LEADGENE BIOMEDICAL, INC.
  • PeproTech Inc.

These companies are expanding portfolios, investing in R&D, and forming strategic collaborations to develop next-generation growth factors with enhanced stability, specificity, and therapeutic applications.

Market Segmentation

By Product Type:

  • Transforming Growth Factor (TGF)
  • Activin
  • Bone Morphogenetic Proteins (BMPs)
  • TGF-beta Proteins
  • Epidermal Growth Factors (EGFs)
  • Platelet-Derived Growth Factors (PDGFs)
  • Fibroblast Growth Factors (FGFs)
  • Insulin-like Growth Factors (IGFs)
  • Vascular Endothelial Growth Factors (VEGFs)
  • Hepatocyte Growth Factors (HGFs)
  • Tumor Necrosis Factors (TNFs)
  • Interleukins
  • Others

By Application:

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Therapy and Ex-Vivo Manufacturing
  • Others

By End User:

  • Pharmaceutical and Biotechnology Companies
  • Research Centres & Academic Institutes
  • Contract Research Organisations

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Growth Factors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Growth Factors Market Outlook, 2020-2033

  • 3.1. Global Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Transforming Growth Factor (TGF)
      • 3.1.1.1. Activin
      • 3.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 3.1.1.3. TGF-beta Proteins
    • 3.1.2. Epidermal Growth Factors (EGFs)
    • 3.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 3.1.4. Fibroblast Growth Factors (FGFs)
    • 3.1.5. Insulin-like Growth Factors (IGFs)
    • 3.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 3.1.7. Hepatocyte Growth Factors (HGFs)
    • 3.1.8. Tumor Necrosis Factors (TNFs)
    • 3.1.9. Interleukins
    • 3.1.10. Others
  • 3.2. Global Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 3.2.1. Oncology
    • 3.2.2. Hematology
    • 3.2.3. Wound Healing
    • 3.2.4. Dermatology
    • 3.2.5. Cardiovascular Disease & Diabetes
    • 3.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 3.2.7. Others
  • 3.3. Global Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Pharmaceutical and Biotechnology Companies
    • 3.3.2. Research Centres & Academic Institutes
    • 3.3.3. Contract Research Organisations
  • 3.4. Global Growth Factors Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Growth Factors Market Outlook, 2020-2033

  • 4.1. North America Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Transforming Growth Factor (TGF)
      • 4.1.1.1. Activin
      • 4.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 4.1.1.3. TGF-beta Proteins
    • 4.1.2. Epidermal Growth Factors (EGFs)
    • 4.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 4.1.4. Fibroblast Growth Factors (FGFs)
    • 4.1.5. Insulin-like Growth Factors (IGFs)
    • 4.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 4.1.7. Hepatocyte Growth Factors (HGFs)
    • 4.1.8. Tumor Necrosis Factors (TNFs)
    • 4.1.9. Interleukins
    • 4.1.10. Others
  • 4.2. North America Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 4.2.1. Oncology
    • 4.2.2. Hematology
    • 4.2.3. Wound Healing
    • 4.2.4. Dermatology
    • 4.2.5. Cardiovascular Disease & Diabetes
    • 4.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 4.2.7. Others
  • 4.3. North America Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Pharmaceutical and Biotechnology Companies
    • 4.3.2. Research Centres & Academic Institutes
    • 4.3.3. Contract Research Organisations
  • 4.4. North America Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Growth Factors Market Outlook, by Product Type, 2020-2033
    • 4.4.2. U.S. Growth Factors Market Outlook, by Application, 2020-2033
    • 4.4.3. U.S. Growth Factors Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Growth Factors Market Outlook, by Product Type, 2020-2033
    • 4.4.5. Canada Growth Factors Market Outlook, by Application, 2020-2033
    • 4.4.6. Canada Growth Factors Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Growth Factors Market Outlook, 2020-2033

  • 5.1. Europe Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Transforming Growth Factor (TGF)
      • 5.1.1.1. Activin
      • 5.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 5.1.1.3. TGF-beta Proteins
    • 5.1.2. Epidermal Growth Factors (EGFs)
    • 5.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 5.1.4. Fibroblast Growth Factors (FGFs)
    • 5.1.5. Insulin-like Growth Factors (IGFs)
    • 5.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 5.1.7. Hepatocyte Growth Factors (HGFs)
    • 5.1.8. Tumor Necrosis Factors (TNFs)
    • 5.1.9. Interleukins
    • 5.1.10. Others
  • 5.2. Europe Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 5.2.1. Oncology
    • 5.2.2. Hematology
    • 5.2.3. Wound Healing
    • 5.2.4. Dermatology
    • 5.2.5. Cardiovascular Disease & Diabetes
    • 5.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 5.2.7. Others
  • 5.3. Europe Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Pharmaceutical and Biotechnology Companies
    • 5.3.2. Research Centres & Academic Institutes
    • 5.3.3. Contract Research Organisations
  • 5.4. Europe Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.2. Germany Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.3. Germany Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.5. Italy Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.6. Italy Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.7. France Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.8. France Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.9. France Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.11. U.K. Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.12. U.K. Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.14. Spain Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.15. Spain Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.17. Russia Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.18. Russia Growth Factors Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Growth Factors Market Outlook, by Product Type, 2020-2033
    • 5.4.20. Rest of Europe Growth Factors Market Outlook, by Application, 2020-2033
    • 5.4.21. Rest of Europe Growth Factors Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Growth Factors Market Outlook, 2020-2033

  • 6.1. Asia Pacific Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Transforming Growth Factor (TGF)
      • 6.1.1.1. Activin
      • 6.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 6.1.1.3. TGF-beta Proteins
    • 6.1.2. Epidermal Growth Factors (EGFs)
    • 6.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 6.1.4. Fibroblast Growth Factors (FGFs)
    • 6.1.5. Insulin-like Growth Factors (IGFs)
    • 6.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 6.1.7. Hepatocyte Growth Factors (HGFs)
    • 6.1.8. Tumor Necrosis Factors (TNFs)
    • 6.1.9. Interleukins
    • 6.1.10. Others
  • 6.2. Asia Pacific Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 6.2.1. Oncology
    • 6.2.2. Hematology
    • 6.2.3. Wound Healing
    • 6.2.4. Dermatology
    • 6.2.5. Cardiovascular Disease & Diabetes
    • 6.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 6.2.7. Others
  • 6.3. Asia Pacific Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Pharmaceutical and Biotechnology Companies
    • 6.3.2. Research Centres & Academic Institutes
    • 6.3.3. Contract Research Organisations
  • 6.4. Asia Pacific Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.2. China Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.3. China Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.5. Japan Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.6. Japan Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.8. South Korea Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.9. South Korea Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.10. India Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.11. India Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.12. India Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.14. Southeast Asia Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.15. Southeast Asia Growth Factors Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Growth Factors Market Outlook, by Product Type, 2020-2033
    • 6.4.17. Rest of SAO Growth Factors Market Outlook, by Application, 2020-2033
    • 6.4.18. Rest of SAO Growth Factors Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Growth Factors Market Outlook, 2020-2033

  • 7.1. Latin America Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Transforming Growth Factor (TGF)
      • 7.1.1.1. Activin
      • 7.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 7.1.1.3. TGF-beta Proteins
    • 7.1.2. Epidermal Growth Factors (EGFs)
    • 7.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 7.1.4. Fibroblast Growth Factors (FGFs)
    • 7.1.5. Insulin-like Growth Factors (IGFs)
    • 7.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 7.1.7. Hepatocyte Growth Factors (HGFs)
    • 7.1.8. Tumor Necrosis Factors (TNFs)
    • 7.1.9. Interleukins
    • 7.1.10. Others
  • 7.2. Latin America Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 7.2.1. Oncology
    • 7.2.2. Hematology
    • 7.2.3. Wound Healing
    • 7.2.4. Dermatology
    • 7.2.5. Cardiovascular Disease & Diabetes
    • 7.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 7.2.7. Others
  • 7.3. Latin America Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Pharmaceutical and Biotechnology Companies
    • 7.3.2. Research Centres & Academic Institutes
    • 7.3.3. Contract Research Organisations
  • 7.4. Latin America Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.2. Brazil Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.3. Brazil Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.5. Mexico Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.6. Mexico Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.8. Argentina Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.9. Argentina Growth Factors Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Growth Factors Market Outlook, by Product Type, 2020-2033
    • 7.4.11. Rest of LATAM Growth Factors Market Outlook, by Application, 2020-2033
    • 7.4.12. Rest of LATAM Growth Factors Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Growth Factors Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Growth Factors Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Transforming Growth Factor (TGF)
      • 8.1.1.1. Activin
      • 8.1.1.2. Bone Morphogenetic Proteins (BMPs)
      • 8.1.1.3. TGF-beta Proteins
    • 8.1.2. Epidermal Growth Factors (EGFs)
    • 8.1.3. Platelet-Derived Growth Factors (PDGFs)
    • 8.1.4. Fibroblast Growth Factors (FGFs)
    • 8.1.5. Insulin-like Growth Factors (IGFs)
    • 8.1.6. Vascular Endothelial Growth Factors (VEGFs)
    • 8.1.7. Hepatocyte Growth Factors (HGFs)
    • 8.1.8. Tumor Necrosis Factors (TNFs)
    • 8.1.9. Interleukins
    • 8.1.10. Others
  • 8.2. Middle East & Africa Growth Factors Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 8.2.1. Oncology
    • 8.2.2. Hematology
    • 8.2.3. Wound Healing
    • 8.2.4. Dermatology
    • 8.2.5. Cardiovascular Disease & Diabetes
    • 8.2.6. Cell Therapy and Ex-Vivo Manufacturing
    • 8.2.7. Others
  • 8.3. Middle East & Africa Growth Factors Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. Research Centres & Academic Institutes
    • 8.3.3. Contract Research Organisations
  • 8.4. Middle East & Africa Growth Factors Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.2. GCC Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.3. GCC Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.5. South Africa Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.6. South Africa Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.8. Egypt Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.9. Egypt Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.11. Nigeria Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.12. Nigeria Growth Factors Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Growth Factors Market Outlook, by Product Type, 2020-2033
    • 8.4.14. Rest of Middle East Growth Factors Market Outlook, by Application, 2020-2033
    • 8.4.15. Rest of Middle East Growth Factors Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Lonza Group AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.3. Merck KGaA
    • 9.4.4. Hoffmann-La Roche Ltd.
    • 9.4.5. Applied Biological Materials (abm), Inc.
    • 9.4.6. Abcam plc
    • 9.4.7. GE Healthcare
    • 9.4.8. Cell Signaling Technology, Inc.
    • 9.4.9. Meridian Bioscience Inc.
    • 9.4.10. Sartorius CellGenix GmbH

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations